EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Major 18 month collaboration in the US using PrecisionPath to provide genetic profiles of cancer tumours.
EKF Diagnostics Holdings plc will announce its preliminary results.
EKF Diagnostics, announces that it has introduced a new diabetic biomarker test that provides a 2-3 week indicator of average blood glucose.
EKF announces the appointment of Panmure Gordon (UK) Limited as its Nominated Adviser and Broker.
EKF Diagnostics Holdings plc provides the following trading update for the year ended 31 December 2014.
EKF Diagnostics announces that it has agreed a collaboration with specialist medtech company ANGLE plc (AIM: AGL), to investigate the combination of ANGLE’s Parsortix circulating tumour cell (CTC) harvesting platform with EKF’s PointMan™ DNA enrichment technology as a liquid biopsy.
Collaboration with specialist medtech company ANGLE to investigate CTC harvesting platform.
EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm point of care (POC) hemoglobin analyzer at Arab Health 2015, 26-29th January, Dubai, UAE. Also on Stand Z1G30, EKF will be discussing its new liquid-stable assay* for early sepsis detection, as well as previewing SensPoint, a new hand-held lactate analyzer with built-in connectivity functions to hospital or laboratory information systems.
Cash payment of £1.425m as a settlement for the total deferred cash consideration due in relation to DiaSpect Medical AB.